With cash in its coffers from last year's sale of Domantis Ltd. to GlaxoSmithKline plc, Peptech Ltd. is buying out EvoGenix Ltd. for A$156 million (US$128.6 million), a 33 percent premium to the last trading price, in a bid to create yet another formidable antibody player. (BioWorld Today) Read More
